Skip to content
Twitter Facebook-f Youtube Instagram Linkedin
NETs Info
Donate
Close Menu
  • Who We Are
    • About Us
    • Our People
    • Our Board
    • Our Ambassadors
    • Consumer Advisory Group
    • International Advisory Panel
    • Governance & Policy
  • Neuroendocrine Cancers
    • What are Neuroendocrine Cancers?
    • Patient Resources
    • Pheos and Paras
    • NET Library
  • I Am a Patient
    • Patient Support
    • Patient Resources
    • NET Nurse
    • Patient Stories
    • Australian NET Specialists
    • Current Clinical Trials
  • I am a HCP
    • Professional Learning
    • HCP – Patient Referral to NET Nurse
    • Current Clinical Trials
    • NET Library
    • HCP Newsletter & Signup
    • Australian NET Specialists
    • Request an In-Service
    • PLANET Registry
    • Order booklets and other resources
  • Get Involved
    • NET Cancer Day 2022
    • Advocate for us
    • Share your story
    • Donate
    • Fundraise
    • In Memoriam
    • Corporate Partners
    • Gifts & Wills
    • Workplace Giving
    • Volunteer
  • What’s On
    • News
    • Newsletter & Signup
    • INCA Newsletter archive
    • Events
  • Shop
  • Contact Us
Donate
  • Who We Are
    • About Us
    • Our People
    • Our Board
    • Our Ambassadors
    • Consumer Advisory Group
    • International Advisory Panel
    • Governance & Policy
  • Neuroendocrine Cancers
    • What are Neuroendocrine Cancers?
    • Patient Resources
    • Pheos and Paras
    • NET Library
  • I Am a Patient
    • Patient Support
    • Patient Resources
    • NET Nurse
    • Patient Stories
    • Australian NET Specialists
    • Current Clinical Trials
  • I am a HCP
    • Professional Learning
    • HCP – Patient Referral to NET Nurse
    • Current Clinical Trials
    • NET Library
    • HCP Newsletter & Signup
    • Australian NET Specialists
    • Request an In-Service
    • PLANET Registry
    • Order booklets and other resources
  • Get Involved
    • NET Cancer Day 2022
    • Advocate for us
    • Share your story
    • Donate
    • Fundraise
    • In Memoriam
    • Corporate Partners
    • Gifts & Wills
    • Workplace Giving
    • Volunteer
  • What’s On
    • News
    • Newsletter & Signup
    • INCA Newsletter archive
    • Events
  • Shop
  • Contact Us

Home » General » Merkel Cell Cancer Evening

Merkel Cell Cancer Evening

  • May 27, 2018

 

Meredith Cummins our NSW Project Officer recently attended this event.
Read her recount below….

An education evening was recently held on 10th May at the Poche Centre. During
the evening I had the opportunity to meet the Chair of the AMIGO's Australasian Merkel Cell Patient Advocacy Group and to
liaise with the multidisciplinary health professionals in attendance. There
have been advances in the management of Merkel Cell Carcinoma (MCC) however
there is still much work to be done for this uncommon cancer. The first
presentation was given from a dermatology perspective – the presence of positive
MCV mutation is a better prognosis. The use of acronym AEIOU in diagnosis of
MCC – A – asymptomatic, E-expending, I – Immune Compromise, O – older than 50yrs and U- UV exposure is
reported that 90% of MCC patients have 3 or greater of the 5 criteria. The
pathology is difficult to differentiate. The role of surgery can be diagnosis,
staging, loco-regional treatment and salvage of recurrent disease. Staging used
is AJCC (T classification) – 27 – 31% with lymphadenopathy. Sentinel Node
Biopsy being performed often means that Adjuvant Radiation Therapy can be avoided;
however, there is a high false negative rate in MCC. From Radiation Oncology
perspective MCC is radiosensitive and doses of Radiation Therapy are around 60
– 66 Grey. Discussion was had regarding
FDG PET imaging and it was stated that FDG likes MCC with 95 % sensitivity in
Stage 2 and 3 disease. Medical Oncology management was presented which
discussed the use of chemotherapy and immune – oncology agents. Somatostatins
can be used as can Lutetium. The new immune-oncology agents such as Avelumab
have shown an early response and can maintain response for 12 – 18 months.
Several trials have reported that immune-oncology agents can be useful in positive
and negative PDL1 candidates. Finally work into multispectral
immunohistochemistry involving viruses was presented.

The Pharmaceutical Benefits Advisory Committee (PBAC) is currently reviewing the drub Avelumab in the treatment of MCC.  If you would like to make a submission as to the importance of more treatment options for rare cancers including MCC, deadline is June 6th click here

Share this post

Subscribe to our eNews

Stay up to date on news and events, clinical trials and new research on neuroendocrine cancers.

Recent posts

World Cancer Day 2023

January 10, 2023

Support Groups Christmas Gatherings

December 20, 2022

NeuroEndocrine Cancer Australia & Norman Family Trust Partnership

December 14, 2022

NeuroEndocrine Cancer Australia partners with Gathered Here to provide the NET community with free online Wills

December 14, 2022
Categories
  • Advocacy
  • Awareness
  • Community Events
  • Education
  • Events
  • Fundraising
  • General
  • In The Media
  • News
  • Research
  • Unicorn Events
PrevPreviousUnicorn Foundation exhibits at 12th Congress WFNMB
NextVale Aretha Franklin, the queen of soulNext

Related Posts

NECA Finalist as NGO of the Year in Prime Awards

We’re thrilled to be announced as one of the finalists in the NGO of The Year category in the 2022 PRIME Awards Australia. The Prime

COVID-19 Information and Resources

A note from our CEO on COVID-19: To our wonderful NET community we stand with you and alongside you as we get through this unprecedented

Expression-of-Interest for consumer participation on Grant Review Committees for the 2022 Priority-driven Collaborative Cancer Research Scheme

Cancer Australia’s Priority-driven Collaborative Cancer Research Scheme (PdCCRS) is an innovative, competitive, annual cancer research projects grant funding scheme. The PdCCRS is conducted by Cancer

32 neuroendocrine tumour presentations at ASCO annual scientific conference

The ASCO Annual Conference was held virtually this year from 29 – 31 May 2020 with 32 Neuroendocrine presentations from this meeting delivered orally, by

View All

Make a difference

How much do you wish to donate?
$50
$100
$250
$500
$1000
Other
NeuroEndocrine Cancer Australia logo white
Twitter Facebook-f Youtube Instagram Linkedin

All donations are tax deductible.
Registered Charity CFN 202607

Who We Are

  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • International Advisory Panel
  • Governance & Policies
  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • International Advisory Panel
  • Governance & Policies

Neuroendocrine Cancers

  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library
  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library

For Patients

  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials
  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials

Get Involved

  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise
  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise

© 2020 NeuroEndocrine Cancer Australia

  • Website by Five Creative